Venus Remedies Ltd's Q4FY25 Quarter Results
- 27 May 2025
Result Summary
- Venus Remedies Ltd reported a 11.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 25.2%.
- Its expenses for the quarter were up by 10.8% QoQ and 30.4% YoY.
- The net profit decreased 46.4% QoQ and decreased 5.0% YoY.
- The earnings per share (EPS) of Venus Remedies Ltd stood at 7.9 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 199.08 | 178.89 | 159.05 | 11.3% | 25.2% |
Total Expenses | 181.61 | 163.92 | 139.32 | 10.8% | 30.4% |
Profit Before Tax | 17.47 | 24.88 | 19.73 | -29.8% | -11.5% |
Tax | 6.96 | 5.28 | 8.67 | 31.8% | -19.7% |
Profit After Tax | 10.51 | 19.60 | 11.06 | -46.4% | -5.0% |
Earnings Per Share | 7.90 | 14.70 | 8.30 | -46.3% | -4.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Venus Remedies Ltd is a pharmaceutical company that specializes in the development, production, and distribution of a diverse range of pharmaceutical products. The company operates primarily in the healthcare and pharmaceutical industry, focusing on critical care and oncology products. Venus Remedies is known for its innovative drug delivery systems and has a strong presence in both domestic and international markets. While specific recent developments are not provided, the company has historically been involved in research and development to expand its product offerings and enhance its market position.
Revenue
In Q4FY25, Venus Remedies Ltd reported a total income of ₹199.08 crore, reflecting an 11.3% increase compared to the previous quarter (Q3FY25) where the total income was ₹178.89 crore. This marks a significant year-over-year growth of 25.2% from Q4FY24, when the total income stood at ₹159.05 crore. The company has experienced consistent revenue growth over the past year, indicating a strong sales performance during this period. The quarter-over-quarter increase can be attributed to various factors such as expanded market reach or increased demand for the company's products.
Profitability
The financial performance of Venus Remedies Ltd in terms of profitability has shown a mixed trend. The company’s profit before tax for Q4FY25 was ₹17.47 crore, which represents a decline of 29.8% compared to Q3FY25, where the profit before tax was ₹24.88 crore. Year-over-year, there was an 11.5% decrease from Q4FY24, which recorded a profit before tax of ₹19.73 crore. The profit after tax for Q4FY25 was ₹10.51 crore, a significant decrease of 46.4% from the previous quarter’s profit after tax of ₹19.60 crore, and a 5.0% decline from Q4FY24's ₹11.06 crore. This decline in profitability, despite increased revenue, suggests an increase in total expenses or other factors impacting the bottom line.
Operating Metrics
Total expenses for Venus Remedies Ltd in Q4FY25 amounted to ₹181.61 crore, an increase of 10.8% from Q3FY25, where expenses were ₹163.92 crore. On a year-over-year basis, this represents a 30.4% increase compared to Q4FY24, which recorded total expenses of ₹139.32 crore. The tax expense for Q4FY25 was ₹6.96 crore, a 31.8% increase from the previous quarter’s tax of ₹5.28 crore, but a 19.7% decrease from the tax expense of ₹8.67 crore in Q4FY24. The earnings per share (EPS) for Q4FY25 was ₹7.90, showing a decline of 46.3% from the previous quarter's EPS of ₹14.70 and a 4.8% decrease from Q4FY24's EPS of ₹8.30. These metrics highlight a significant increase in expenses, impacting the company's profitability metrics despite the revenue growth.